Research programme: small molecule therapeutics - OXIS InternationalAlternative Names: OXS 4135; OXS 4235; p62-zz inhibitors - OXIS International
Latest Information Update: 06 Aug 2015
At a glance
- Originator ID4 Pharma
- Developer ID4 Pharma; OXIS International
- Class Small molecules
- Mechanism of Action NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors; SQSTM1 protein inhibitors; Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma; Osteolysis